Last reviewed · How we verify
placebo+chemotherapy
This drug works by enhancing the effects of chemotherapy.
This drug works by enhancing the effects of chemotherapy. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer.
At a glance
| Generic name | placebo+chemotherapy |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Chemotherapy enhancer |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The exact molecular target or receptor is unknown, but it is believed to work by sensitizing cancer cells to chemotherapy, allowing for a more effective treatment.
Approved indications
- Metastatic breast cancer, Metastatic non-small cell lung cancer
Common side effects
- Nausea
- Fatigue
- Hair loss
- Anemia
- Neutropenia
Key clinical trials
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children (NA)
- Procedural Framing and Epidural Steroid Injection Outcomes (NA)
- A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (PHASE3)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo+chemotherapy CI brief — competitive landscape report
- placebo+chemotherapy updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI